{"id":"secretin-biologically-derived-porcine","brandName":"secretin, biologically derived porcine","genericName":"secretin, biologically derived porcine","companyId":"eunice-kennedy-shriver-national-institute-of-child-health-and-human-development","companyName":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","phase":"phase_3","status":"active","modality":"Small molecule","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"Secretin, a biologically derived porcine drug, has been evaluated in a Phase 3 trial for autism but lacks FDA approval. It is not commercially available and has no current revenue. The drug's mechanism involves regulating gastrointestinal functions, but its efficacy in autism remains inconclusive.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Secretin works by binding to secretin receptors on the surface of pancreatic acinar cells, which triggers a signaling cascade that leads to the release of digestive enzymes and bicarbonate into the small intestine. This helps to neutralize stomach acid and facilitate the digestion of nutrients.","oneSentence":"Secretin is a hormone that stimulates the pancreas to release digestive enzymes and bicarbonate.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"trials":[],"indications":{"approved":[{"name":"Treatment of pancreatic fistula"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}